IMPORTANT
Eligible patient ages:
- 40y.o. -70y.o.
- Samples cannot be accepted for patients outside of this age bracket

This test requires a blood draw, so please ensure you can refer to a phlebotomist in the clients area before you order this test.

Trucheck is a revolutionary screening test, based on a simple blood draw.

Trucheck Intelli is a comprehensive wellness status check qualifying no tumour activity, but which also screens for early detection of 70+ types of cancers such as Melanoma, Thyroid, Lung, Breast, Liver, Gastro-Intestinal, amongst others.

Recommended for:

• Asymptomatic individuals who are at high risk or have a family history of cancer.
• Individuals who want to include this test in their yearly health check-up.

To date people have believed that they were well until they are told that they are not, but often this might be in stage III or IV cancer, with treatment and prognosis being hard. The promise of this type of screening is that it provides a baseline in times of wellness, and then if a tumour does develop between the screening period and the follow up test (which should be encouraged to be annually in people over the age of 40), then there would be a high degree of confidence that this cancer would be in an early stage, and thus treatment is likely to be far easier, and with much fewer side effects, and much better prognosis.

The sample is very time-sensitive, therefore we request that you please contact your Practitioner Support Person or contact us: info@nordic-labs.com BEFORE ordering to ensure smooth return of the sample.

Trucheck is a revolutionary screening test, based on a simple blood draw. 

Trucheck Intelli is a comprehensive wellness status check qualifying no tumour activity, but which also screens for early detection of 70+ types of cancers such as Melanoma, Thyroid, Lung, Breast, Liver, Gastro-Intestinal, amongst others.

Although the aim of the test is to provide peace of mind of no tumour development and confirm a healthy status, Trucheck's value is also in its ability for early detection in asymptomatic tumours, and in doing so, has the potential to reduce the heavy effects of cancer treatment, and in turn reduce mortality.

The last decade has seen a tremendous amount of research in the field of cancer screening. Instead of thinking "cancer", we should begin thinking about "no cancer" status and ensure regular screening so that when a tumour development occurs it can be detected and treated at an early stage. This is particularly pertinent to population groups that are defined as high and moderate risk for developing cancer. Trucheck really allows for this status check to become part of a regular health screen and check-up. 

• Trucheck screens for circulating tumour cells from 70 solid tumours.
• Trucheck should be used as a screen and it is expected that more than 95% will have a status where no cancer is found.
• Trucheck is a blood-based test which can detect cancers in asymptomatic individuals.
• Trucheck has unprecedented sensitivity and specificity even in early cancer stages.
• Trucheck is the culmination of years of collaborative international research and innovation and has been developed, tested and validated on > 57.000 individuals.

Methodology 

Immunocytochemistry ( ICC)

Markers

C-ETACs ( Circulating ensembles of tumour-associated cells)
CTCs  (Circulating Tumor Cells)

Specimen

Whole blood 

Container

• 3 x EDTA tubes (purple colour cap) of 10 ml each

Volume

20 mL

Patient preparation

Not received blood transfusion at least 10 days prior to collection of the sample.
Not positive for HIV / HBV / HCV.

1. Akolkar, Dadasaheb, et al. "Circulating ensembles of tumor-associated cells: a redoubtable new systemic hallmark of cancer." International journal of cancer 146.12 (2020): 3485-3494.
2. Ranade, Anantbhushan, et al. "Hallmark Circulating Tumor-Associated Cell Clusters Signify 230 Times Higher One-Year Cancer Risk." Cancer Prevention Research 14.1 (2021): 11-16.
3. Gaya, Andrew, et al. "Evaluation of circulating tumor cell clusters for pan-cancer noninvasive diagnostic triaging." Cancer cytopathology 129.3 (2021): 226-238.